BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 31502865)

  • 41. Construction of a novel mRNA-miRNA-lncRNA network and identification of potential regulatory axis associated with prognosis in colorectal cancer liver metastases.
    Lu C; Luo X; Xing C; Mao Y; Xu Y; Gao W; Wang W; Zhan T; Wang G; Liu Z; Yu C
    Aging (Albany NY); 2021 Jun; 13(11):14968-14988. PubMed ID: 34081622
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Genome-Wide Analysis of Prognostic lncRNAs, miRNAs, and mRNAs Forming a Competing Endogenous RNA Network in Hepatocellular Carcinoma.
    Lin P; Wen DY; Li Q; He Y; Yang H; Chen G
    Cell Physiol Biochem; 2018; 48(5):1953-1967. PubMed ID: 30092571
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Transcriptomic analysis of high-throughput sequencing about circRNA, lncRNA and mRNA in bladder cancer.
    Li M; Liu Y; Zhang X; Liu J; Wang P
    Gene; 2018 Nov; 677():189-197. PubMed ID: 30025927
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Integrated analysis of long non-coding RNA‑associated ceRNA network reveals potential lncRNA biomarkers in human lung adenocarcinoma.
    Sui J; Li YH; Zhang YQ; Li CY; Shen X; Yao WZ; Peng H; Hong WW; Yin LH; Pu YP; Liang GY
    Int J Oncol; 2016 Nov; 49(5):2023-2036. PubMed ID: 27826625
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comprehensive bioinformatics analysis of ribonucleoside diphosphate reductase subunit M2(RRM2) gene correlates with prognosis and tumor immunotherapy in pan-cancer.
    Wu L; Yin L; Ma L; Yang J; Yang F; Sun B; Nianzeng X
    Aging (Albany NY); 2022 Oct; 14(19):7890-7905. PubMed ID: 36202136
    [TBL] [Abstract][Full Text] [Related]  

  • 46. TCGA dataset‑based construction and integrated analysis of aberrantly expressed long non‑coding RNA mediated competing endogenous RNA network in gastric cancer.
    He W; Zhang D; Li X; Wu J; Yang X; Wang Q; Lu W; Jiang J; Wu C
    Oncol Rep; 2018 Dec; 40(6):3511-3522. PubMed ID: 30272352
    [TBL] [Abstract][Full Text] [Related]  

  • 47.
    Li J; Wang X; Wang Y; Yang Q
    Epigenomics; 2020 Jun; 12(12):989-1002. PubMed ID: 32432496
    [No Abstract]   [Full Text] [Related]  

  • 48. Identification of Potential Prostate Cancer-Related Pseudogenes Based on Competitive Endogenous RNA Network Hypothesis.
    Jiang T; Guo J; Hu Z; Zhao M; Gu Z; Miao S
    Med Sci Monit; 2018 Jun; 24():4213-4239. PubMed ID: 29923546
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comprehensive Analysis of Differentially Expressed Profiles of lncRNAs/mRNAs and miRNAs with Associated ceRNA Networks in Triple-Negative Breast Cancer.
    Yang R; Xing L; Wang M; Chi H; Zhang L; Chen J
    Cell Physiol Biochem; 2018; 50(2):473-488. PubMed ID: 30308479
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Analysis of lncRNA-Associated ceRNA Network Reveals Potential lncRNA Biomarkers in Human Colon Adenocarcinoma.
    Zhang Z; Qian W; Wang S; Ji D; Wang Q; Li J; Peng W; Gu J; Hu T; Ji B; Zhang Y; Wang S; Sun Y
    Cell Physiol Biochem; 2018; 49(5):1778-1791. PubMed ID: 30231249
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comprehensive characterization of lncRNA-mRNA related ceRNA network across 12 major cancers.
    Zhang Y; Xu Y; Feng L; Li F; Sun Z; Wu T; Shi X; Li J; Li X
    Oncotarget; 2016 Sep; 7(39):64148-64167. PubMed ID: 27580177
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Construction and analysis of mRNA, miRNA, lncRNA, and TF regulatory networks reveal the key genes associated with prostate cancer.
    Ye Y; Li SL; Wang SY
    PLoS One; 2018; 13(8):e0198055. PubMed ID: 30138363
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Integrated analysis of competing endogenous RNA (ceRNA) networks in subacute stage of spinal cord injury.
    Wang N; He L; Yang Y; Li S; Chen Y; Tian Z; Ji Y; Wang Y; Pang M; Wang Y; Liu B; Rong L
    Gene; 2020 Feb; 726():144171. PubMed ID: 31669638
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Long non-coding RNA MALAT1 regulates BLCAP mRNA expression through binding to miR-339-5p and promotes poor prognosis in breast cancer.
    Zheng L; Zhang Y; Fu Y; Gong H; Guo J; Wu K; Jia Q; Ding X
    Biosci Rep; 2019 Feb; 39(2):. PubMed ID: 30683807
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Role of the long non-coding RNA PVT1 in the dysregulation of the ceRNA-ceRNA network in human breast cancer.
    Conte F; Fiscon G; Chiara M; Colombo T; Farina L; Paci P
    PLoS One; 2017; 12(2):e0171661. PubMed ID: 28187158
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Construction of implantation failure related lncRNA-mRNA network and identification of lncRNA biomarkers for predicting endometrial receptivity.
    Feng C; Shen JM; Lv PP; Jin M; Wang LQ; Rao JP; Feng L
    Int J Biol Sci; 2018; 14(10):1361-1377. PubMed ID: 30123082
    [TBL] [Abstract][Full Text] [Related]  

  • 57. SSTR5‑AS1 functions as a ceRNA to regulate CA2 by sponging miR‑15b‑5p for the development and prognosis of HBV‑related hepatocellular carcinoma.
    Xu J; Zhang J; Shan F; Wen J; Wang Y
    Mol Med Rep; 2019 Dec; 20(6):5021-5031. PubMed ID: 31638225
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The SNHG16/miR-30a axis promotes breast cancer cell proliferation and invasion by regulating RRM2.
    Du SM
    Neoplasma; 2020 May; 67(3):567-575. PubMed ID: 32122142
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comprehensive analysis of dysregulated exosomal long non-coding RNA networks associated with arteriovenous malformations.
    Li X; Gui Z; Han Y; Yang X; Wang Z; Zheng L; Zhang L; Wang D; Fan X; Su L
    Gene; 2020 May; 738():144482. PubMed ID: 32087271
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Inferences of individual drug responses across diverse cancer types using a novel competing endogenous RNA network.
    Zhang Y; Li X; Zhou D; Zhi H; Wang P; Gao Y; Guo M; Yue M; Wang Y; Shen W; Ning S; Li Y; Li X
    Mol Oncol; 2018 Sep; 12(9):1429-1446. PubMed ID: 29464864
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.